Biosciences

Our planet is changing. So is our journalism. This weekly newsletter is part of a CBC News initiative entitled "Our Changing Planet" to show and explain the effects of climate change. Keep up with the latest news on our Climate and Environment page.Sign up here to get this newsletter in your inbox every Thursday.This week: Christmas trees have the potential to spread unwanted critters What has 2 (or 3) wheels and helps reduce oil consumption? Here's why food waste is a major climate change issue Christmas trees…

Biopharmaceutical company PlasmaGen Biosciences has raised Rs 225 crore (roughly $27 million) in equity funding from UK-based investment management firm Artian Investments, Ashish Rameshchandra Kacholia and other high-net-worth individuals (HNIs). Kacholia is known to pick up stakes in companies and invest in public markets. Elevate Your Tech Prowess with High-Value Skill CoursesOffering CollegeCourseWebsiteIIM LucknowIIML Executive Programme in FinTech, Banking & Applied Risk ManagementVisitIIT DelhiIITD Certificate…

You’ve probably heard of Colossal Biosciences’ plans to bring the woolly mammoth back to life, but now it’s betting on yet another extinct creature. The company also wants to revive the dodo, yet another push towards genetically engineering creatures of the past. Of course, it isn’t as simple as cloning the discovered DNA and making something out of it. The company’s big plan to revive the woolly mammoth essentially boils down to making a mammoth and elephant hybrid, allowing it to protect the animal’s native…

Colossal Biosciences, which is known for its plans to revive extinct animals, says that it hopes to revive the woolly Mammoth in just four years. De-extinction has become a topic in quite a few circles in recent years, and the company has been at the forefront of the quest to restore long-dead species to the Earth. The goal to revive the woolly mammoth by 2027 is a huge one, and the company has put much stock into how it plans to bring these extinct creatures back to life – as well as why it wants to do that.…

Biotech company Enzene Biosciences, a subsidiary of Mumbai-based drug maker Alkem Laboratories, has raised $50 million (or roughly Rs 408 crore) in fresh equity funding from Eight Roads Ventures and healthcare investor F-Prime Capital.In a press statement, Enzene said it would leverage the fresh funds to enhance its manufacturing capabilities and drive expansion in its core market of India and the US.Pune-based Enzene focuses on producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals.Enzene has…

Trevor Martin’s Mammoth Biosciences aims to use CRISPR technology to democratize disease detection. Join this TechCrunch Live event to hear from Trevor Martin and Mayfield investor Ursheet Parikh on how Mammoth Biosciences positioned itself to achieve the lofty goal. Spoiler: Trevor Martin spent time putting the basics in place to ensure future success. This TechCrunch Live event opens on October 5 at 11:30 a.m. PDT/2:30 p.m. EDT with networking. The interview begins at 12:00 p.m. PDT followed…

The vegan food market was pegged as a $27 billion industry last year, a figure that’s expected to more than double within a decade. This hasn’t gone unnoticed by the major food and beverage incumbents such as Nestlé, which launched a plant-based dairy line under the Wunda brand last year, while rival Unilever has been doubling down on its vegan offerings. But any company looking to develop successful plant-based food alternatives often face challenges when trying to replicate certain goods…